Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XC221 in Uncomplicated Influenza or Acute Respiratory Viral Infections
NCT05544916Phase 3Completed
- Sponsor
- Valenta Pharm
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aterixen in influenza, acute respiratory viral infection (ARVI), sponsored by Valenta Pharm. Started Aug 2022; status: completed.
02
Drugs
aterixen
03
Conditions
influenzaacute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT05544916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544916.